Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for alcohol-related disorders. The company’s lead product candidate, AD04, is an investigational intravenous therapy designed to accelerate the metabolism of ethanol in the blood, potentially reducing the severity and duration of acute alcohol intoxication. Adial applies a bio-mimetic enzymatic approach to address a significant unmet medical need in emergency and clinical settings.
Adial’s research and development efforts center on advancing AD04 through preclinical and clinical studies, with the goal of establishing safety and efficacy profiles that support regulatory approval. The company’s proprietary technology platform leverages engineered enzymes to break down ethanol, differentiating its approach from traditional supportive care measures. By targeting the root cause of intoxication rather than merely managing symptoms, Adial aims to deliver a therapeutic option for patients, clinicians and first responders.
Headquartered in the United States, Adial Pharmaceuticals maintains its operations in Florida, where it oversees product manufacturing partnerships, clinical trial coordination and regulatory interactions. The company has built a network of collaborators and contract research organizations to facilitate its clinical programs and to position AD04 for potential global development following initial regulatory review.
Adial’s leadership team is led by Michael Sindoni, who serves as President and Chief Executive Officer. Under his guidance, the company has prioritized strategic research alliances, intellectual property protection and the pursuit of key regulatory milestones. Moving forward, Adial plans to advance its clinical pipeline while exploring additional therapeutic applications of its enzymatic technology platform.
AI Generated. May Contain Errors.
